1 completed, 1 recruiting, 1 terminated. 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Raymond Chung: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk Atorvastatin 20mg, Placebo - Liver Fibroses, Cirrhosis | Phase 2 | Recruiting | Raymond Chung | 60 | 2023-05-10 | 2026-10-07 |
| Pegylated Interferon Lambda Treatment for COVID-19 Pegylated interferon lambda - COVID-19, COVID | Phase 2 | Terminated | Raymond Chung | 14 | 2020-06-22 | 2022-07-21 |
| Multi-center Study to Transplant Hepatitis-C Infected Kidneys glecaprevir/pibrentasvir treatment - Renal Failure Chronic, Hepatitis C | Phase 4 | Completed | Raymond Chung | 30 | 2019-04-10 | 2022-01-26 |
COVID-19 (1) · Coronavirus Infections (1) · Fibrosis (1) · Hepatitis C (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Atorvastatin (1) · glecaprevir (1)
United States (3)